Clinical trial
A Phase Ib Study of Pembrolizumab (MK-3475) in Chinese Subjects With Locally Advanced or Metastatic Melanoma (Keynote-151)
NCT02821000 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib Study of Pembrolizumab (MK-3475) in Chinese Subjects With Locally Advanced or Metastatic Melanoma (Keynote-151)
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 8, 2016
- Completion date
- November 30, 2022
- Enrollment
- 103 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.